Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.59 |
| ▸ | AKT2 | P31751 | 6/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.46 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800151 | 0.79 | DRD2 (0.63) | JAK1AKT2NUDT1PBKGSK3B | |
| SCHEMBL30356007 | 0.75 | JAK1 (1.00) | JAK1 | |
| SCHEMBL12605440 | 0.74 | AKT2 (0.70) | AKT2NUDT1PBKGSK3BPRKCI | |
| SCHEMBL18440877 | 0.74 | AKT2 (0.65) | AKT2NUDT1PBKGSK3BAKT1 | |
| SCHEMBL12605438 | 0.74 | AKT2 (0.65) | AKT2NUDT1PBKGSK3BPRKCI | |
| SCHEMBL12605530 | 0.73 | AKT2 (0.68) | AKT2NUDT1PBKGSK3BPRKCI | |
| SCHEMBL2799562 | 0.72 | AKT2 (0.67) | AKT2NUDT1PBKGSK3B | |
| SCHEMBL30040884 | 0.72 | HRH4 (0.52) | AKT2NUDT1AKT1DRD4HTR1A | |
| SCHEMBL25505716 | 0.72 | HRH4 (0.52) | AKT2NUDT1AKT1DRD4HTR1A | |
| Hydrochloric Acid SCHEMBL2800609 | 0.71 | AKT2 (0.65) | AKT2NUDT1PBKGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885AKT2 208/4885NUDT1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.